Major Complete Response Rate in Very High-Risk Bladder Cancer With Combo Treatment
MedPage Today,
WASHINGTON -- Adding immunotherapy to standard treatment for non-muscle invasive bladder cancer (NMIBC) achieved complete…
WASHINGTON -- Adding immunotherapy to standard treatment for non-muscle invasive bladder cancer (NMIBC) achieved complete…
Atezolizumab (Tecentriq) in combination with BCG induction and maintenance therapy did not produce a significant benefit in…
Combining Tecentriq (atezolizumab) with Bacillus Calmette-Guérin (BCG) therapy did not lead to better outcomes compared with…
Atezolizumab (Tecentriq) plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy did not significantly improve…